Sign In
Buy AKBA
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 01'st Jun 2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
08:00am, Thursday, 28'th May 2026
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
03:51pm, Thursday, 07'th May 2026
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
09:51am, Thursday, 07'th May 2026
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
07:00am, Thursday, 07'th May 2026
Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million ; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compare
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 04'th May 2026
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, gr
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
04:05pm, Thursday, 30'th Apr 2026
Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT CAMBRIDGE, Mass.
New Strong Sell Stocks for April 28th
05:01am, Tuesday, 28'th Apr 2026
EADSY, AKBA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2026.
Ionis Pharmaceuticals (NASDAQ:IONS) and Akebia Therapeutics (NASDAQ:AKBA) Financial Analysis
04:11am, Saturday, 18'th Apr 2026
Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) and Akebia Therapeutics (NASDAQ: AKBA - Get Free Report) are both medical companies, but which is the superior business? We will compare the two
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
08:00am, Monday, 13'th Apr 2026
CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
08:00am, Tuesday, 07'th Apr 2026
CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease
JPMorgan Chase & Co. Has $2.71 Million Holdings in Akebia Therapeutics, Inc. $AKBA
04:45am, Monday, 06'th Apr 2026
JPMorgan Chase and Co. lessened its holdings in Akebia Therapeutics, Inc. (NASDAQ: AKBA) by 39.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Com
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets
01:05am, Saturday, 04'th Apr 2026
Akebia Therapeutics (NASDAQ: AKBA) used its R&D Day presentation to outline a strategy centered on expanding its commercial anemia franchise while advancing three kidney disease pipeline programs: pra
Akebia Therapeutics, Inc. $AKBA Shares Sold by Assenagon Asset Management S.A.
03:22am, Friday, 03'rd Apr 2026
Assenagon Asset Management S.A. cut its stake in Akebia Therapeutics, Inc. (NASDAQ: AKBA) by 94.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commi
